PSYENCE BIOMEDICAL LTD.

Based in Toronto, Ontario, Psyence Biomedical Ltd. develops botanical psilocybin-based psychedelic medicines for psychiatric and palliative care applications. The company's lead product candidate is PEX010, a capsule containing naturally sourced psilocybin currently in Phase IIb clinical trials. PEX010 is being evaluated for the treatment of anxiety, depression, post-traumatic stress disorder, and adjustment disorder in patients with incurable cancer in palliative care settings.

The company conducts its clinical development through partnerships, including a collaboration with iNGENu Pty Ltd to run Phase IIb trials of PEX010 in psilocybin-assisted psychotherapy. Psyence Biomedical also maintains a strategic collaboration with PsyLabs related to ibogaine production. The company operates as a subsidiary of Psyence Group Inc. and is listed on Nasdaq.

With 12 full-time employees, Psyence Biomedical operates at an early-stage development scale. The company is incorporated in Ontario, Canada and maintains its primary operations in Toronto.